ProCE Banner Activity

Recent Advances in the Treatment of Eosinophilic Esophagitis

Clinical Thought

Read expert commentary on recent advances in the treatment of eosinophilic esophagitis (EoE), including recent updates in the use dupilumab and budesonide oral suspension and how to incorporate these agents into practice to tailor care and improve the lives of patients with EoE.

Released: September 20, 2024

Expiration: September 19, 2025

Share

Faculty

Jonathan M Spergel

Jonathan M Spergel, MD, PhD

Professor of Pediatrics
Chief, Allergy Section
Division of Allergy and Immunology
Children's Hospital of Philadelphia
Perelman School of Medicine at University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Takeda Pharmaceuticals U.S.A., Inc.; and Regeneron Pharmaceuticals, Inc and Sanofi.

Regeneron Pharmaceuticals, Inc

Sanofi

Takeda Pharmaceuticals U.S.A., Inc.

Disclosure

Primary Author

Jonathan M Spergel, MD, PhD

Professor of Pediatrics
Chief, Allergy Section
Division of Allergy and Immunology
Children's Hospital of Philadelphia
Perelman School of Medicine at University of Pennsylvania
Philadelphia, Pennsylvania

Jonathan M. Spergel, MD, PhD: consultant/advisor/speaker: ARS Pharma, Regeneron, Sanofi; researcher: Bristol Myers Squibb, Novartis, Regeneron, Sanofi.